Quotes 5-day view Delayed Nasdaq
06/02/2023
06/05/2023
06/06/2023
06/07/2023
06/08/2023
Date
130.51(c)
128.9(c)
126.9(c)
125.61(c)
124.1787
Last
2 357 539
3 206 071
2 491 424
3 161 355
1 473 739
Volume
+1.55%
-1.23%
-1.55%
-1.02%
-1.14%
Change
Estimated financial data (e) (USD)
Sales 2023
7 338 M
-
-
Net income 2023
-974 M
-
-
Net cash position 2023
6 940 M
-
-
P/E ratio 2023
-57,0x
Yield 2023
-
Sales 2024
6 632 M
-
-
Net income 2024
-1 540 M
-
-
Net cash position 2024
5 889 M
-
-
P/E ratio 2024
-31,8x
Yield 2024
-
Capitalization
47 884 M
47 884 M
-
EV / Sales 2023
5,58x
EV / Sales 2024
6,33x
Nbr of Employees
3 900
Free-Float
91,0%
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in...
All news about MODERNA, INC.
News in other languages on MODERNA, INC.
Analyst Recommendations on MODERNA, INC.
ETFs positioned on MODERNA, INC. ETFs and Trackers with Trackinsight
Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MODERNA, INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
125,61 $
Average target price
211,96 $
Spread / Average Target
68,7%
Please enable JavaScript in your browser's settings to use dynamic charts.